More on ASND

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+180.0% Growth)
- Ratings (9.6 Score)
- Holders

Upcoming Events

- Earnings (11/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Ascendis Pharma (NQ:ASND)
Delayed: 225.25 -1.37 (0.6%)
Prev. Close $226.62  
Open$226.62 
52 Wk High$21.79 
52 Wk Low$11.92 
Day High$226.76 
Day Low$223.78 
P/E N/A  
EPS$-0.07 
Volume680,329 

Friends, Peers and Foes (?): A1SN34, ASG, VRTX, BIIB, ONC (more...)

Oct 16, 2026 02:59 PM Form 6-K Ascendis Pharma A/S For: Oct 16
Oct 16, 2026 08:30 AM EU panel recommends Ascendis Pharma's navepegritide for achondroplasia
Oct 16, 2026 08:29 AM Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
Oct 15, 2026 09:21 AM Ascendis Pharma (ASND) PT Lowered to $269 at UBS
Oct 14, 2026 05:02 PM Form 6-K Ascendis Pharma A/S For: Oct 14
Oct 6, 2026 09:15 AM Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Sep 29, 2026 04:03 PM Form 6-K Ascendis Pharma A/S For: Sep 29
Sep 28, 2026 04:08 PM Form 4 Ascendis Pharma A/S For: Apr 14 Filed by: BIENAIME JEAN JACQUES
Sep 16, 2026 06:55 AM H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)
Sep 15, 2026 01:57 PM Ascendis Pharma (ASND) call put ratio 1 call to 1 put a share price down 12.6%
View All Articles

Entities mentioned with ASND

View All Entities